Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

Ranya Dajani, our former glorified press-secretary, is now a business development consultant at Cabaletta Bio. Why such a small company would hire a secretary?

https://www.linkedin.com/company/cabalettabio/about/

Overview
Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The platform is based on the revolutionary Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell products for the treatment of B cell malignancies. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop the CAAR T technology to treat B cell-mediated autoimmune diseases. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus vulgaris (mPV), which is a rare skin disorder that causes painful blisters and sores on mucous membranes leading to severe and sometimes debilitating and life-altering effects. An IND submission is planned for 2H19.

Website http://www.cabalettabio.com
Industry Biotechnology
Company size 2-10 employees
Headquarters Radnor Township, Pennsylvania
Type Privately Held
Founded 2017